Improving antitumor responses and animal survival compared with Increasing the frequency of monotherapy with anti-PD-L1 or VSV-mIFNβ-NISReducing tumor burden in various organs of the studied miceeffector CD4+ and CD8+ TILs in the TME. The gene discussed is CD8A; the disease is neoplasm.